Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1996 1
1999 2
2000 4
2001 4
2002 3
2003 3
2004 4
2005 5
2006 6
2007 6
2008 3
2009 8
2010 4
2011 4
2012 6
2013 3
2014 6
2015 11
2016 12
2017 12
2018 16
2019 9
2020 12
2021 19
2022 9
2023 12
2024 12
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Garin E, et al. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7. Lancet Gastroenterol Hepatol. 2021. PMID: 33166497 Free article. Clinical Trial.
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F. Houot R, et al. Among authors: itti e. Nat Med. 2023 Oct;29(10):2593-2601. doi: 10.1038/s41591-023-02572-5. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37710005 Free PMC article. Clinical Trial.
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
Cazelles C, Belhadj K, Vellemans H, Camus V, Poullot E, Gaulard P, Veresezan L, Itti E, Becker S, Carvalho M, Dupuis J, Le Bras F, Lemonnier F, Roulin L, El Gnaoui T, Jardin F, Mounier N, Tilly H, Haioun C. Cazelles C, et al. Among authors: itti e. Leuk Lymphoma. 2021 Sep;62(9):2161-2168. doi: 10.1080/10428194.2021.1901090. Epub 2021 Mar 25. Leuk Lymphoma. 2021. PMID: 33764240 Free article.
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
Claudel A, Cottereau AS, Bachy E, Itti E, Feugier P, Rossi C, Lemonnier F, Camus V, Daguindau N, Cartron G, Nicolas-Virelizier E, Mboumba DL, Cardoso C, Bommier C, Tessoulin B, Fruchart C, Gilbert A, Durot E, Fleck E, Pica GM, Zerazhi H, Guidez S, Cheminant M, Sarkozy C, Xerri L, Vercellino L, Trabelsi N, Gomes L, Portugues C, Viailly PJ, Delfau-Larue MH, Morschhauser F. Claudel A, et al. Among authors: itti e. Blood. 2025 Aug 21;146(8):913-925. doi: 10.1182/blood.2024027727. Blood. 2025. PMID: 40499012 Clinical Trial.
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.
Camus V, Molina T, Desmots F, Blanc-Durand P, Kanoun S, Moslemi A, Ruminy P, Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Houot R, Thieblemont C, Maisonneuve H, Claves F, Bouabdallah K, Haioun C, Damaj GL, Fornecker LM, Noel R, Feugier P, Sibon D, Cartron G, Bonnet C, Bernard W, Kraeber-Bodéré F, Bodet-Milin C, Jais JP, Brière J, Rossi C, Elsensohn MH, Chartier L, Itti E, Jardin F, Fest T. Camus V, et al. Among authors: itti e. Blood Adv. 2025 May 13;9(9):2232-2246. doi: 10.1182/bloodadvances.2024015577. Blood Adv. 2025. PMID: 40030008 Free PMC article. Clinical Trial.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Among authors: itti e. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study.
Nault JC, Boubaya M, Wartski M, Dohan A, Pol S, Pop G, Soussan M, Sutter O, Costentin C, Roux J, Sengel C, Lequoy M, Montravers F, Menu Y, Pageaux GP, Goulart DM, Guiu B, Luciani A, Nahon P, Dioguardi Burgio M, Wagner M, Maksud P, Mulé S, Allaire M, Sidali S, Coilly A, Besson FL, Lewin M, Regnault H, Hollande C, Amaddeo G, Ronot M, Ganne-Carrié N, Itti E, Bloch-Queyrat C, Levy V, Lebtahi R, Chalaye J, Bouattour M. Nault JC, et al. Among authors: itti e. Lancet Gastroenterol Hepatol. 2025 Apr;10(4):306-314. doi: 10.1016/S2468-1253(25)00011-1. Epub 2025 Feb 20. Lancet Gastroenterol Hepatol. 2025. PMID: 39987937 Clinical Trial.
Whole-Body Functional MRI and PET/MRI in Multiple Myeloma.
Mulé S, Reizine E, Blanc-Durand P, Baranes L, Zerbib P, Burns R, Nouri R, Itti E, Luciani A. Mulé S, et al. Among authors: itti e. Cancers (Basel). 2020 Oct 27;12(11):3155. doi: 10.3390/cancers12113155. Cancers (Basel). 2020. PMID: 33121132 Free PMC article. Review.
Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis.
Annabi MS, Carter-Storch R, Zaroui A, Galat A, Oghina S, Kharoubi M, Bezard M, Derumeaux G, Fanen P, Lemonnier F, Poullot E, Itti E, Gallet R, Teiger E, Pibarot P, Damy T, Clavel MA. Annabi MS, et al. Among authors: itti e. J Am Heart Assoc. 2024 Jul 2;13(13):e034723. doi: 10.1161/JAHA.124.034723. Epub 2024 Jun 21. J Am Heart Assoc. 2024. PMID: 38904242 Free PMC article.
172 results